BTIG Research Lowers Caris Life Sciences (NASDAQ:CAI) Price Target to $38.00

Caris Life Sciences (NASDAQ:CAI) had its price objective cut by equities research analysts at BTIG Research from $45.00 to $38.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 88.68% from the company’s current price.

Several other research firms also recently commented on CAI. Robert W. Baird increased their price objective on Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday. Canaccord Genuity Group increased their target price on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Evercore set a $38.00 price objective on Caris Life Sciences in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a report on Monday, December 29th. Finally, Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.50.

Caris Life Sciences Trading Up 4.7%

Shares of CAI stock opened at $20.14 on Friday. The stock has a 50 day moving average price of $24.42. The company has a market cap of $5.68 billion and a P/E ratio of -43.78. Caris Life Sciences has a 12 month low of $17.15 and a 12 month high of $42.50. The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36.

Caris Life Sciences (NASDAQ:CAI) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The business had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. During the same period in the prior year, the business earned ($1.73) earnings per share. The company’s revenue for the quarter was up 125.4% on a year-over-year basis.

Insiders Place Their Bets

In other news, insider Luke Thomas Power sold 62,250 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total value of $1,654,605.00. Following the sale, the insider directly owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. This represents a 38.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Caris Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its stake in shares of Caris Life Sciences by 14.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after acquiring an additional 1,180,200 shares during the last quarter. Braidwell LP lifted its position in shares of Caris Life Sciences by 6.8% during the 4th quarter. Braidwell LP now owns 7,816,142 shares of the company’s stock valued at $210,880,000 after buying an additional 500,000 shares in the last quarter. PointState Capital LP grew its stake in shares of Caris Life Sciences by 73.0% during the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after acquiring an additional 2,834,986 shares during the period. Orbimed Advisors LLC raised its position in shares of Caris Life Sciences by 2.7% during the 4th quarter. Orbimed Advisors LLC now owns 3,116,011 shares of the company’s stock valued at $84,070,000 after purchasing an additional 81,153 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Caris Life Sciences by 185.0% during the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock valued at $65,974,000 after buying an additional 1,587,176 shares in the last quarter.

Trending Headlines about Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.